
Why Burnout Happens—and Why Rest Isn't the Cure
The surprising truth about burnout and why rest isn't the answer
Burnout isn't what most people think. It's not just being tired. It's not simply working too hard or taking on too much. Burnout means you're frustrated with lack of growth.
If you're not progressing, you have to work harder just to maintain the same results. Setbacks take a bigger toll. You might start to question your ability and future success, which creates more uncertainty and low confidence. But if you're in flow, with a purpose, you don't notice these things. Entrepreneurs who are fully aligned with their 'why' and seeing daily progress don't succumb to burnout. They get on with their mission.
Burnout is a common challenge among entrepreneurs, with recent surveys showing that 34.4% of founders report experiencing burnout, and 26.9% struggle with poor work-life balance. The intensity of entrepreneurial life is reflected in the fact that 45% of entrepreneurs say they feel burned out from juggling too many responsibilities, while 30% report being constantly stressed. Burnout is deeply tied to the unique pressures of entrepreneurship, including high responsibility, blurred work-life boundaries, and ongoing financial uncertainty.
A founder will build something impressive, scale it to a certain point, then hit a wall. Not because they lack skill or drive, but because growth has plateaued. When progress stops, energy depletes. It's no coincidence. Progress fuels purpose. Stagnation breeds burnout.
When you're working, but not moving. Running on empty. Wheels spinning in the dirt. Gearbox not engaged. Normal, yes. Permanent, no. With a few reframes, burnout becomes avoidable.
Most advice about burnout focuses on symptoms, not causes. It tells you to take a break. Get more sleep. Practice self-care. All good things. But they won't fix the real problem. Sleep won't save you if your calendar is packed with obligations you resent. Meditation won't rescue you from a business model that drains your spirit. Here's what to do instead.
You feel anxious opening your inbox. New notifications trigger a stress response. Tasks that once excited you now feel like a drag. Your creativity is harder to summon. Solutions don't appear. Small decisions overwhelm you. What to eat for lunch becomes a daily ordeal. You forget why simple choices matter. Everything feels equally heavy.
You resent clients you used to enjoy. Their messages make your stomach drop. Their reasonable requests suddenly feel like impositions. You catch yourself thinking, "Why don't they just figure it out themselves?"
Your body and mind send clear messages before full burnout hits. Learn to read them.
Burnout goes away when growth restarts. Attacking symptoms while ignoring causes guarantees the cycle continues. Find what's blocking your progress. Remove it. Watch your energy return.
First, identify what's actually draining you. Which clients make your heart sink? Which projects feel like pushing rocks uphill? Which parts of your business bring zero joy? Write it down. Get specific. Energy vampires in business hide behind phrases like "should" and "have to" and "industry practice."
Ask yourself: If I could eliminate three things from my business tomorrow, what would they be? What would I feel if they disappeared? Relief speaks volumes about what needs to change.
Your business exists to serve you. Not trap you. If it feels like a cage, change the rules. Clear signs you need a break from your business include running on cortisol, fantasising about other work, and cutting corners.
Look at your calendar. Does it reflect your priorities? Or does it showcase everyone else's? Start saying no to what doesn't serve your growth. Delete recurring meetings that drain more than they deliver.
Review your business model. The path out of burnout requires working smarter, not harder. Create assets that generate income while you sleep. Build systems that multiply your impact without multiplying your hours.
Vacations provide temporary relief. But reasons, challenges, and wins create lasting energy. Your brain craves meaningful problems to solve. Give it some.
Set a goal that scares and excites you. Something requiring your best thinking and most creative solutions. Make it specific. Make it measurable. Make it matter to you personally, not just your bottom line.
What would make you proud to accomplish this year? What would fundamentally change your business trajectory? What problem, if solved, would unlock everything else? Find that challenge. Attack it with everything you've got.
Energy transfers between people. Surround yourself with stagnant people, you'll stagnate too. If your best friend or closest colleague is easily overwhelmed, it will rub off on you. Connect with growth-minded individuals and watch your own thinking expand.
Who do you spend most time with? Are they building, creating, advancing? Or complaining, maintaining, staying safe? Your environment shapes your mindset more than you realize.
This applies to clients too. Find clients that energize you by setting clear boundaries and trusting your gut about who you work with. One draining client can sap energy from an entire week. Choose wisely.
Entrepreneurs are resilient when they have a mission. Burnout happens when you forget why you started. When your mission loses meaning. When growth stalls and momentum dies. Rest alone won't save you. You have to rediscover your purpose. You have to start seeing progress.
Spot the warning signals early. Reignite your momentum. Rebuild your environment. Create worthy challenges. Choose your influences carefully. Your business can energize rather than exhaust you. What needs to change to make growth possible again? Answer that question to break the burnout cycle for good.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
13 minutes ago
- CBS News
RFK Jr. taps allies and COVID vaccine critics among picks for CDC advisory panel. Here's who's on the list.
Health and Human Services Robert F. Kennedy Jr. announced Wednesday he's naming eight new advisers to serve on the Centers for Disease Control and Prevention's vaccine recommendations committee, after firing the committee's entire previous roster of 17 advisers. "All of these individuals are committed to evidence-based medicine, gold-standard science, and common sense. They have each committed to demanding definitive safety and efficacy data before making any new vaccine recommendations," Kennedy said Wednesday in a post on X. Kennedy's picks circumvented the usual CDC process for selecting members of the Advisory Committee on Immunization Practices. In previous administrations, career agency officials — not political leaders — vetted potential experts before forwarding them to the department for the secretary's approval. The panel's influential recommendations are closely watched because they are directly tied to federal policies, like which vaccines insurers are required to cover. The picks announced by Kennedy include some close allies of the secretary and his inner circle. One of them, Dr. Robert Malone, worked on early research related to mRNA vaccine technology but was accused during the COVID-19 pandemic of spreading misinformation about the mRNA vaccines. He was with Kennedy and President Trump at the Trump election night celebration in Florida. "On the basis of data from all over the world, approximately three years ago it was my impression that the risk/benefit ratio of these products did not merit continued use in any cohort," Malone posted last month on his Substack about the mRNA COVID vaccines. Like Kennedy, Malone has questioned the benefits of measles vaccines during the recent record outbreak in Texas, which killed two children, and he has promoted unproven treatments for the virus. Another member picked by Kennedy is Dr. Martin Kulldorff, an epidemiologist who co-authored the pandemic-era Great Barrington Declaration criticizing COVID-19 restrictions, along with now-NIH Director Dr. Jay Bhattacharya. Bhattacharya has described Kulldorff as a close friend. Kulldorff previously worked with the CDC's outside vaccine advisers, before authoring an opinion piece in 2021 criticizing the agency's decision to pause use of Johnson & Johnson's COVID-19 vaccine over safety concerns. He claimed he was fired from working with the committee over the opinion piece. Kulldorff later claimed he was fired from Harvard University for criticizing COVID-19 vaccine requirements. Dr. Cody Meissner, a pediatrics professor who previously served as a member of the Food and Drug Administration's own vaccines panel — the Vaccines and Related Biological Products Advisory Committee – was also named to the committee. Meissner opposed COVID-19 vaccine requirements for children. He also co-authored an opinion piece with now-FDA Commissioner Dr. Marty Makary speaking out against masking of children during the pandemic. Another former member of the FDA vaccines panel who was picked by Kennedy is Vicky Pebsworth, a regional director of the National Association of Catholic Nurses. Pebsworth spoke at a 2020 meeting of the FDA vaccines committee, where she identified herself as the research director for the National Vaccine Information Center and "mother of a child injured by his 15-month well-baby shots in 1998." She said the center's position was that any "coercion and sanctions to persuade adults to take an experimental vaccine, or give it to their children, is unethical and unlawful." Kennedy also praised another pick, MIT professor Retsef Levi, saying: "Dr. Levi has collaborated with public health agencies to evaluate vaccine safety, including co-authoring studies on mRNA COVID-19 vaccines and their association with cardiovascular risks." Levi previously called for more detailed data from the COVID-19 vaccine trials, suggesting that changes to how Pfizer's shot was produced may have caused side effects. But Levi faced criticism for a paper co-authored with Florida Surgeon General Dr. Joseph Ladapo, which was cited in the state's move to recommend that young men not get mRNA COVID-19 vaccines. Experts condemned the paper for misleading methods that could inflate the risk. The views on vaccines of several of Kennedy's other picks are less clear. Kennedy said Dr. Michael A. Ross "contributed to national strategies for cancer prevention and early detection, including those involving HPV immunization," working with the CDC's breast and cervical cancer committee. Ross is described by Kennedy as an obstetrics and gynecology professor at George Washington University and Virginia Commonwealth University, though his name does not appear on directories for either university. Spokespeople for the two institutions did not immediately respond to a request for comment. Dr. James Pagano, described by Kennedy as a "strong advocate for evidence-based medicine," appears to have published little about vaccines or medicine. Records from the Medical Board of California list Pagano as being retired. Another Kennedy pick, Dr. Joseph Hibbeln, retired from the National Institutes of Health in 2020. His research portfolio previously covered nutritional intake of fatty acids like omega-3. Kennedy described him as bringing "expertise in immune-related outcomes, psychiatric conditions, and evidence-based public health strategies."


CBS News
40 minutes ago
- CBS News
Cook County jury awards $20.5 million to family of girl who died from toxic levels of morphine
A Cook County jury awarded more than $20 million in damages to the family of an 11-year-old girl who died from toxic levels of morphine. In October 2020, Ava Wilson was recovering from leukemia when she went for a follow-up appointment at Advocate Children's Hospital. During her appointment, she was crying from pain, and had difficulty walking, according to her family's attorneys. Lab tests revealed she had low platelet counts, low blood cell counts, high liver enzymes, and low blood pressure. She was discharged from Advocate Children's Hospital with instructions to take 15 milligrams of morphine every four hours, triple the amount of her previous prescriptions. A nurse practitioner also increased her gabapentin prescription. Approximately 36 hours after getting home, she died in her sleep from acute drug toxicity of several substances, including lethal levels of morphine in her system at the time of her death. Her family's attorneys said the hospital should have admitted Ava to the hospital to get her blood pressure under control and treat the cause of her pain, but simply sent her home with excessive pain medications. "Ava's body was yelling out to these clinicians, 'help me!', and they just ignored it," attorney Matthew Williams said. After a civil trial, a jury awarded her family $20.5 million in damages. "While nothing will ease the depth of Ava's loved ones' pain, the family appreciates that the jury recognized that Ava's death was preventable and that she should still be with them today," attorney Aaron Boeder said.


Medscape
41 minutes ago
- Medscape
Fast Five Quiz: Late-Onset Pompe Disease
Multiple genetic variants have been associated with LOPD. However, the c.-32-13T>G splice site variant is found in up to 90% of adults and 50% of pediatric patients. Patients with LOPD often have compound heterozygous genotypes, with one allele carrying the common c.-32-13T>G splice-site variant and the other harboring a more deleterious GAA mutation (eg, nonsense, frameshift, or large deletion). Other variants— such as and c.1935C>A — are more commonly seen in infantile forms of Pompe disease. Learn more about the pathophysiology of LOPD. Diagnosis of LOPD typically follows a two-step approach: first, measuring GAA enzyme activity (often via dried blood spot assay) followed by confirmatory molecular genetic testing to identify pathogenic GAA variants. Although once considered a first-line diagnostic tool for LOPD, muscle biopsy is no longer preferred due to its invasive nature and the non-specificity of histologic findings. Muscle biopsy may still be considered in rare, ambiguous cases when enzyme and genetic testing are inconclusive or conflicting. CK levels might be elevated in some patients but are nonspecific and primarily serve to raise clinical suspicion. Learn more about the workup for LOPD. Enzyme replacement therapy (ERT) has significantly changed the natural history of the disease by improving survival and stabilizing motor and respiratory function. However, key limitations in skeletal muscle uptake and variability in clinical response remain. This is due to low expression of the mannose-6-phosphate receptor in muscle tissue, which hampers enzyme internalization. As a result, patients might experience a limited or plateaued response. Newer approaches, including modified ERT and gene therapy, are being developed to address this issue. High toxicity to cardiac muscle, uniform patient response, and development of cardiac hypertrophy have not been reported as key limitations. Learn more about treatment options for LOPD. NBS programs have reshaped the understanding of Pompe disease, particularly LOPD. A significant proportion of screen-positive newborns harbor genetic variants associated with LOPD, including pseudo deficiency alleles and variants of uncertain significance. These individuals are often asymptomatic at birth and might not develop symptoms for years, if at all. This has raised important clinical questions around monitoring, counseling, and when (or whether) to initiate therapy; expanded screening has also revealed that the true prevalence of LOPD might be higher than historical estimates suggested. Learn more about the management of LOPD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication. Lead image: UCSF/Science Source